Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41417-022-00435-8 http://scihub22266oqcxt.onion/10.1038/s41417-022-00435-8 35194198!8861484!35194198     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\35194198.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Gene+Ther 2023 ; 30 (6): 785-793 Nephropedia Template TP {{tp|p=35194198|t=2023. Next generation self-replicating RNA vectors for vaccines and immunotherapies |pdf=|usr=}}{{35194198}} gab.com Text Next generation self-replicating RNA vectors for vaccines and immunotherapies JO: Cancer Gene Ther http://www.kidney.de/pget.php?&tw=1&pmid=35194198 #FOAvip RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy. In addition to conventional mRNA platforms now approved for prophylactic SARS-CoV2 vaccines, synthetic self-replicating RNA vaccines are currently being evaluated in the clinic for infectious disease and oncology. The prototypical srRNA vectors in clinical development are derived from alphaviruses, specifically Venezuelan Equine Encephalitis Virus (VEEV). While non-VEEV alphaviral strains have been explored as single cycle viral particles, their use as synthetic vectors largely remains under-utilized in clinical applications. Here we describe the potential commonalities and differences in synthetic alphaviral srRNA vectors in host cell interactions, immunogenicity, cellular delivery, and cargo expression. Thus, unlike the current thinking that VEEV-based srRNA is a one-size-fits-all platform, we argue that a new drug development approach leveraging panels of customizable, synthetic srRNA vectors will be required for clinical success. Twit Text FOAVip Next generation self-replicating RNA vectors for vaccines and immunotherapies ????Cancer Gene Ther http://www.kidney.de/pget.php?&tw=1&pmid=35194198 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35194198 #FOAvip English Wikipedia <ref>{{Cite pmid|35194198}}</ref> Next generation self-replicating RNA vectors for vaccines and immunotherapies #MMPMID35194198 Aliahmad P; Miyake-Stoner SJ; Geall AJ; Wang NS Cancer Gene Ther 2023[Jun]; 30 (6): 785-793 PMID35194198show ga RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy. In addition to conventional mRNA platforms now approved for prophylactic SARS-CoV2 vaccines, synthetic self-replicating RNA vaccines are currently being evaluated in the clinic for infectious disease and oncology. The prototypical srRNA vectors in clinical development are derived from alphaviruses, specifically Venezuelan Equine Encephalitis Virus (VEEV). While non-VEEV alphaviral strains have been explored as single cycle viral particles, their use as synthetic vectors largely remains under-utilized in clinical applications. Here we describe the potential commonalities and differences in synthetic alphaviral srRNA vectors in host cell interactions, immunogenicity, cellular delivery, and cargo expression. Thus, unlike the current thinking that VEEV-based srRNA is a one-size-fits-all platform, we argue that a new drug development approach leveraging panels of customizable, synthetic srRNA vectors will be required for clinical success. |*COVID-19[MESH] |*Vaccines[MESH] |*Viral Vaccines/genetics[MESH] |Animals[MESH] |Horses/genetics[MESH] |Immunotherapy[MESH] |RNA, Viral[MESH]Next generation self-replicating RNA vectors for vaccines and immunoth(epmc).pdf DeepDyve Pubget Overpricing